Identification of Differentially Expressed microRNAs in Metastatic Ovarian Cancer

Gu, Yang; Zhang, Shulan

doi:10.21203/rs.2.23093/v2

Cited by 6 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The miR-210-3p is upregulated in most solid tumors, and its levels correlate with a negative clinical outcome [44]. The miR-210 is a marker associated with bone [45]. More interestingly, it is a marker associated with nerve [46].…”

Section: Discussionmentioning

confidence: 99%

Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing

2020

Clin Rheumatol

View full text Add to dashboard Cite

Background The early detection of psoriatic arthritis (PSA) poses a challenge to rheumatologists, even when their diagnosis is aided by sonography. In order to facilitate early detection of PSA among patients with psoriasis (PSO), we retrospectively analyzed of the relationships between serological markers and comorbidities in 629 psoriatic patients, 102 of which had PSA, while the other 527 had PSO. Results Serological markers were found not to be useful in distinguishing between PSA and PSO (p > 0.05 for all comparisons). The prevalence rate of PSA among PSO patients was around 19.4%. Two components of metabolic syndrome-hyperlipidemia (2.94%) and gout (4.9%)-were significantly more prevalent in PSA patients than in PSO patients (p < 0.05). The odds ratio for PSA is 15.94 in patients with hyperlipidemia with a 95% confidence interval (CI) of 1.64-154.80; meanwhile, the odds ratio for PSA is 3.83 in patients with gout with a 95% CI of 1.19-12.31. Allergic rhinitis (5.88%) was more prevalent in PSA patients than in PSO patients (p < 0.01). The odds ratio was 8.17 in patients with allergic rhinitis with a 95% CI of 2.26-29.50. Plasma hs-miR-210-3p distinguishes PSA from PSO, and its levels can also be distinguished from PSA after treated with anti-TNFα biologics agents (both p < 0.05). Conclusions No clinical available serology markers, but hyperlipidemia, gout, axial spondylopathy (inflammatory back pain), or allergic rhinitis, could differentiate between psoriatic arthritis from psoriasis. Plasma hs-miR-210-3p and comorbidities may differentiate psoriatic arthritis from psoriasis. Key Points • Clinical manifestations and comorbidities are different between psoriatic arthritis and psoriasis only patients. • Traditional serology markers are similar between psoriatic arthritis and psoriasis-only patients. • Plasma hs-miR-210-3p distinguishes PSA from PSO, and its levels can also be distinguished from PSA after treated with anti-TNFα biologics agents in our study.

show abstract

Section: Discussionmentioning

confidence: 99%

Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing

2020

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…As intrinsic regulators, miRNAs have been shown to play critical roles in chondrocyte proliferation, differentiation, and endochondral ossification 16‐19 . In addition, aberrant miRNA expression is involved in many bone‐related disorders, including osteoarthritis, osteoporosis, and bone tumors 20‐22 . To the best of our knowledge, the role of miRNAs in the endochondral ossification of the acetabular roof has not yet been analyzed in the DDH setting.…”

Section: Introductionmentioning

confidence: 99%

Chondrocyte suppression is mediated by miR‐129‐5p via GDF11/SMAD3 signaling in developmental dysplasia of the hip

Liu

Deng

Ding

et al. 2020

Journal Orthopaedic Research

View full text Add to dashboard Cite

Recent studies have shown that developmental dysplasia of the hip (DDH) during childhood and in animal models is associated with impaired endochondral ossification of the roof of the acetabulum, yet the molecular mechanism of this pathology remains unknown. To address this, an animal model of DDH was established in 4‐week‐old New Zealand white rabbits by cast immobilization of knee extension. Fifty‐six rabbits of DDH were involved in this study, including 21 male rabbits and 25 female rabbits. High‐throughput RNA sequencing identified 18 differentially expressed microRNAs; miR‐129‐5p downregulation was further confirmed by quantitative polymerase chain reaction. Bioinformatics and luciferase reporter assay identified growth differentiation factor 11 (GDF11) as the target gene of miR‐129‐5p in vitro. miR‐129‐5p downregulation increased GDF11 expression, which induced the phosphorylation of SMAD family member 3. As a result, the expression of runt‐related transcription factor 2, Indian hedgehog homolog, and collagen type X was inhibited in vitro. Meanwhile, Alizarin Red S and Von Kossa staining revealed reduced formation of mineralized nodules by chondrocytes after miR‐129‐5P downregulation compared with the control. Additionally, proliferation assays and flow cytometry confirmed the suppression of chondrocyte proliferation and G1 cell cycle arrest following miR‐129‐5p downregulation. These findings indicate that miR‐129‐5p is able to suppress chondrocyte proliferation and hypertrophic differentiation and decrease mineralization via the miR‐129‐5p/GDF11/SMAD3 axis. This could present the underlying cause for the observed DDH‐associated ossification impairment of the acetabular roof.

show abstract

“…miR-324-5p is increased in end-stage osteoarthritis by regulating hedgehog signaling and osteogenesis in human MSCs (53) and it is also downregulated in the bone marrow of osteoporotic patients. (54) By searching in the miRWalk database, we have found that miR-324-5p targets three genes (FOXO1/FOXO3, FOSB, and RUNX2) that promote osteoblastogenesis and consequently would interfere negatively with osteoblast differentiation and bone mineralization. Karvande and colleagues (55) have shown that the bone formation induced by PTH therapy was related to the increase in miR-451a serum levels.…”

Section: Discussionmentioning

confidence: 99%

A Signature of Circulating miRNAs Associated With Fibrous Dysplasia of Bone: the mirDys Study

Legrand

Millet

Merle

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Fibrous dysplasia (FD) is a rare bone disease caused by activating mutations of GNAS encoding the Gsα protein, enhancing cyclic adenosine monophosphate (cAMP) production by overstimulation of adenylyl cyclase and impairing osteoblastic differentiation. The clinical presentation ranges from asymptomatic to polyostotic forms with severe disability, explained by the mosaic distribution of the GNAS mutation. Physicians have to deal with the gap of knowledge in FD pathogenesis, the absence of prognostic markers and the lack of specific treatment. The identification of specific biomarkers for FD is an important step to improve the clinical and therapeutic approaches. An epigenetic regulation driven by microRNAs (miRNAs), known as promising biomarkers in bone disease, could be involved in FD. We have sought circulating miRNAs that are differentially expressed in FD patients compared to controls and would reflect dysregulations of osteogenesis-related genes and bone disorder. The global miRNA profiling was performed using Next Generation Sequencing in patient serum collected from a discovery cohort of 20 patients (10 polyostotic and 10 monostotic) and 10 controls. From these, we selected 19 miRNAs for a miRNA validation phase from serum of 82 patients and 82 controls, using real-time qPCR. Discovery screening identified 111 miRNAs differentially expressed in patient serum, after adjusting for the false discovery rate (FDR). Among the 82 patients, 55% were polyostotic, and 73% were women with a mean age of 42 years. Six miRNAs (miR-25-3p, miR-93-5p, miR-182-5p, miR-324-5p, miR-363-3p, and miR-451a) were significantly overexpressed in serum, with FDR <0.05. The expression level of these six miRNAs was not associated with the FD severity. In conclusion, we identified a signature of circulating miRNAs associated with FD. These miRNAs are potential negative regulators of gene expression in bone cell progenitors, suggesting their activity in FD by interfering with osteoblastic and osteoclastic differentiation to impair bone mineralization and remodeling processes.

show abstract

Identification of Differentially Expressed microRNAs in Metastatic Ovarian Cancer

Cited by 6 publications

References 31 publications

Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing

Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing

Chondrocyte suppression is mediated by miR‐129‐5p via GDF11/SMAD3 signaling in developmental dysplasia of the hip

A Signature of Circulating miRNAs Associated With Fibrous Dysplasia of Bone: the mirDys Study

Contact Info

Product

Resources

About